Theraclion SA represents values of innovation, excellence, and patient-centric approach. With a strong commitment to improving healthcare outcomes, Theraclion focuses on developing advanced medical technologies and solutions. The company's corporate philosophy revolves around the principles of customer satisfaction, continuous improvement, and social responsibility. Theraclion SA aims to revolutionize the medical industry by delivering cutting-edge treatments and diagnostic tools that cater to the individual needs of patients. With its emphasis on research and development, Theraclion strives to offer safe, effective, and minimally invasive solutions to enhance the quality of life for patients worldwide.

Theraclion SA is primarily present in France, where its headquarters are located. The company focuses on providing innovative medical solutions and is recognized for its expertise in the field of non-invasive medical technologies. Theraclion's advanced medical devices have gained recognition and acceptance in many countries worldwide. While expanding its global presence, Theraclion has also established partnerships and collaborations in various regions to extend the reach of its cutting-edge medical solutions.Overall, Theraclion SA primarily operates in France but strives to make its innovative medical technologies available to patients and healthcare providers globally.

Theraclion SA, a leading healthcare company, has achieved several significant milestones. Firstly, it successfully developed and launched its innovative Echotherapy system, allowing non-invasive treatment of benign tumors and breast fibroadenomas. Additionally, Theraclion SA received clearance from the FDA to market its equipment in the United States, highlighting its commitment to global expansion. The company further expanded its reach by establishing partnerships with renowned medical institutions and distributors worldwide, aiding in the accessibility of its cutting-edge technology. Theraclion SA's dedication to research and development has also resulted in various clinical studies and publications, solidifying its position as a pioneer in advanced medical solutions.

Theraclion SA, a leading medical technology company, has a rich history and background that has shaped its success today. Established in 2004, Theraclion focuses on developing innovative and non-invasive solutions for a variety of medical indications. With its headquarters in France, the company specializes in high-intensity focused ultrasound (HIFU) technology, which enables precise and localized treatments. Theraclion SA has a strong commitment to clinical research and collaboration with leading medical institutions worldwide. Through its dedication to improving patient care and providing effective therapies, Theraclion SA has solidified its position as a trusted name in the medical device industry.

The main competitors of Theraclion SA in the market are Hologic Inc., EDAP TMS SA, and Philips Healthcare.

Theraclion SA is primarily active in the medical technology industry.

Theraclion SA operates under a business model focused on medical technology and innovation. The company specializes in creating advanced medical devices for the treatment of various conditions, including both benign and malignant tumors. Using high-intensity focused ultrasound (HIFU) technology, Theraclion SA's devices provide non-invasive treatment options that are precise, safe, and effective. By harnessing the power of ultrasound, their products allow for targeted tissue ablation, avoiding the need for surgery or other invasive procedures. Theraclion SA's commitment to developing cutting-edge solutions in the medical field, particularly in the field of ultrasound therapy, distinguishes their business model and reflects their dedication to improving patient outcomes.

Az Theraclion P/E mutatója 3,29.

Az Theraclion KUV 1,26.

Az AlleAktien Minőségi Score Theraclion esetében 5/10.

A várt Theraclion forgalma 12,36 Mió. EUR.

A(z) várt Theraclion nyereség 4,75 Mió. EUR.

Theraclion SA is a leading provider of medical solutions based on the innovative HIFU technology (High Intensity Focused Ultrasound). The company is headquartered in Malakoff, France, and offers a wide range of products and services specifically tailored to the needs of physicians and patients in the fields of oncology, gynecology, and dermatology. Theraclion focuses on the development, manufacturing, and marketing of HIFU solutions based on the latest research and knowledge in medical science. Its main products include echotherapy and sonovein, both of which offer a safe, effective, and non-invasive treatment option that allows patients to recover quickly and without the risks of surgery. Echotherapy is an innovative technology developed for the treatment of breast tumors, thyroid adenomas, and uterine fibroids. It is based on the use of focused ultrasound that can penetrate deep into the body to destroy tumors and growths without damaging the surrounding tissue. This treatment is non-invasive and has minimal downtime, making it a promising option for patients who are not suitable for surgery or reject it. Sonovein is a novel technology for the non-invasive treatment of varicose veins. It uses HIFU technology to selectively destroy the vein wall and close the blood vessels. This improves blood circulation and reduces pain and swelling. Sonovein is an effective and safe alternative method to surgery for varicose veins. In addition to these two main products, Theraclion also offers various services, including training and education for physicians, device application training, and after-sales support. The company has built a strong network of distribution partners in Europe, Asia, and the Middle East to promote the spread of its products on a global level. Overall, Theraclion has developed a robust and holistic business model based on creating value for physicians and patients through the provision of innovative and effective medical solutions. The company has a strong culture of innovation that allows it to continuously improve and expand its products and services to meet the requirements of the rapidly changing healthcare market. With its proven HIFU technology and dedicated team of experts, Theraclion is well positioned to grow in the future and inspire talents in the field of medical research.

A(z) Theraclion évente alkalommal oszt ki 0 EUR összegű osztalékot.

A Theraclion esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Theraclion ISIN kódja: FR0010120402.

A Theraclion WKN-je A112C8.

Az Theraclion tőzsdei rövidítése ALTHE.PA.

Az elmúlt 12 hónapban a(z) Theraclion osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Theraclion várhatóan 0 EUR összegű osztalékot fog fizetni.

A(z) Theraclion jelenlegi osztalékhozama .

A(z) Theraclion negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Theraclion az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 EUR összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Theraclion a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Theraclion által 2024. 11. 18.-án/én fizetett 0 EUR összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 11. 18.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 11. 18. időpontban történt.

2023 évben a Theraclion 0 EUR összegű osztalékot fizetett ki.

Az Theraclion osztalékait EUR fizeti ki.